A phase III prospective randomized comparison of imatinib at a dose of 400mg in combination with peg-interferon-alpha2a (Peg-IFNa2a) or cytarabine (Ara-C) versus imatinib at a dose of 600mg versus imatinib a dose of 400mg for previously untreated chronic myelogenous leukemia (CML) in chronic phase

Trial Profile

A phase III prospective randomized comparison of imatinib at a dose of 400mg in combination with peg-interferon-alpha2a (Peg-IFNa2a) or cytarabine (Ara-C) versus imatinib at a dose of 600mg versus imatinib a dose of 400mg for previously untreated chronic myelogenous leukemia (CML) in chronic phase

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Imatinib (Primary) ; Cytarabine; Peginterferon alfa-2a
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT
  • Most Recent Events

    • 10 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
    • 02 Jun 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top